Title: <u>Patient-Reported Outcomes</u> Correlate with <u>Clinical Outcomes</u> in Patients with

Idiopathic Pulmonary Fibrosis

Authors and affiliations: *Soumik Purkayastha[1,2], Suha Kadura[3], Cathie Spino[4],*

*Ganesh Raghu[*3].*

[1]Department of Biostatistics and Health Data Science, University of Pittsburgh,

Pittsburgh, PA, USA.

[2]Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System,

US Department of Veterans Affairs, Pittsburgh, PA, USA.

[3]Division of Pulmonary, Critical Care and Sleep Medicine, Center for Interstitial Lung

Diseases, Department of Medicine, University of Washington, Seattle, WA, USA

[4]Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

[*]**Corresponding author:**

Ganesh Raghu, University of Washington, Campus Box 356175, Seattle, WA 98195,

USA. Email: <u>graghu@uw.edu</u>

Contributions:

1. *Soumik Purkayastha:* Data analyses, interpretation of result, writing first draft,

revised versions and collated inputs from all authors of the manuscript.

2. *Suha Kadura:* Data gathering, interpretation of result, writing first draft, revised

versions and collated inputs from all authors of the manuscript.

3. *Cathie Spino:* Reviewed data analyses and interpretation, reviewed manuscript

and provided input.

4. *Ganesh Raghu:* Designed the trial and study protocol, enrolled consenting

participants in the study, interpretation of results, supervised the conduct of trial

and execution of the trial; manuscript writing.

All authors reviewed the drafts of manuscript, provided input, contributed to writing the

manuscript and approved the final letter for submission.

28   **ABSTRACT**

Background: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive

fibrosis and declining quality of life. Patient-reported outcomes (PROs) provide a more

comprehensive understanding of a patient's experience and health status than clinical

measures (COs) alone, capturing how patients feel, function, and experience their

health. However, the relationship between PROs and COs remains incompletely

understood in this population.

Methods: We performed a secondary analysis of data from the YES-IPF trial,

examining 60 IPF patients who completed a 12-week modified yoga program or

continued usual activities. Pearson correlations between 21 PROs and 6 COs (FVC:

absolute and percent-predicted, DLCO: absolute and percent-predicted, 6-minute walk

test, and GAP: Gender-Age-Physiology index) were assessed at baseline and week. p-

values were adjusted using the Benjamini-Hochberg method across 21 PROs for each

CO measured.

Findings: Several significant correlations were observed between PROs and COs; key

findings include total L-IPF correlating with absolute FVC having baseline $r = -0.33$

($p = 0.03$) and 12-week $r = 0.42$ ($p < 0.01$), total L-IPF correlating with 6MWT having

baseline $r = -0.43$ ($p < 0.01$) and 12-week $r = -0.37$ ($p = 0.02$), shortness of breath

R-scale-PF correlating with absolute DLCO having baseline $r = -0.35$ ($p = 0.04$) and

12-week $r = -0.49$ ($p < 0.01$), total KBILD correlating with percent-predicted FVC

having baseline $r = 0.38$ ($p = 0.03$) and 12-week $r = 0.43$ ($p < 0.01$), and K-BILD

Breathlessness and Activities score correlating with GAP score having baseline

$r = -0.42$ ($p = 0.02$) and 12-week $r = -0.40$ ($p = 0.02$).

Interpretation: In IPF patients, breathlessness-specific PROs report correlation with

COs of disease severity, while sleep-related and psychological domains demonstrate

weaker or minimal correlations. This highlights that PROs and traditional COs measure

related but distinct aspects of IPF, supporting their complementary use in clinical trials

and patient care.

Funding: No funding support was received for this study.

Trial Registration: Registered with ClinicalTrials.gov (NCT0284862)

MAIN TEXT

Idiopathic pulmonary fibrosis is a progressive lung disease significantly impacting patients' quality of life. Patient-reported outcomes are increasingly recognized for their ability to capture patient experience of health, encompassing how they feel and function, which may not be reflected by clinical outcomes alone [1]. Understanding the physical, emotional, and social impacts of patients with idiopathic pulmonary fibrosis, including the well-established burdens of dyspnea and cough, and the increasing recognition of fatigue, is paramount [1,2]. While both patient-reported and clinical outcomes are valuable, patient-reported outcomes have not correlated with disease progression, defined as decline in forced vital capacity in patients with idiopathic pulmonary fibrosis in clinical trials to date.

The Yoga Effect on Quality-of-Life Study Among Patients with Idiopathic Pulmonary Fibrosis (YES-IPF) trial demonstrated that a 12-week modified yoga program improved specific patient-reported outcomes in patients with idiopathic pulmonary fibrosis, without concurrent significant changes in clinical outcomes like forced vital capacity [3]. This prompted us to explore baseline as well as week 12 correlations for all patient-reported and clinical outcomes measured in the trial.

We analyzed data from 60 participants with well-defined idiopathic pulmonary fibrosis in accordance with the established criteria for diagnosis [4] who participated in the YES-IPF trial (ClinicalTrials.gov: NCT02848625). Descriptive statistics for these outcomes are presented in Table 1. Next, we computed pairwise Pearson correlations between 21

patient-reported outcomes (derived from seven validated instruments: the *Living with*

Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire [2,3,5], *Raghu-Scale for Pulmonary*

Fibrosis (R-scale-PF) questionnaire [3,6], *King's Brief Interstitial Lung Disease (KBILD)*

questionnaire [3,7], *EuroQol-5D-5L*, *Hospital Anxiety and Depression Scale (HADS)* [3],

Patient-Reported Outcomes Measurement Information System (PROMIS): *Sleep*

Disturbance (SD) and *Sleep-Related Impairment (SRI)*[8] and *Epworth Sleepiness Scale*

(ESS)[9]) and 6 clinical outcomes (*Forced Vital Capacity (FVC)*: *absolute* and *percent-*

predicted, *Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)*: *absolute* and

percent-predicted, *6-minute walk test (6MWT) distance, and the Gender-Age-*

Physiology (GAP) index). While the first five clinical outcomes were measured during

the trial, we also considered the GAP for this analysis. The GAP index is a validated

prognostic staging system for idiopathic pulmonary fibrosis patients. Correlations were

tested for significance cross-sectionally at baseline and at week 12. Due to some

missing patient-reported or clinical outcomes data at either time point (missingness

counts ranged from 0 to 4 patients), we performed complete case analyses for each

correlation. To control for multiple comparisons while maintaining the exploratory nature

of this pilot study, p-values were adjusted using the Benjamini-Hochberg procedure [10] to

control false discovery rate. All analyses used R (version 4.4.1).

Patient-reported outcomes and clinical measures remained relatively stable from

baseline to week 12. At baseline, patients demonstrated moderate disease burden with

mean FVC of 74.8% predicted (SD 21.44), DLCO of 54.2% predicted (SD 18.27), and

6MWT distance of 1290 feet (SD 401.7). L-IPF cough and dyspnea reported mean

scores of 26.3 (SD 24.2) and 23.0 (SD 21.9), respectively. K-BILD overall mean was 74.7

(SD 18.2), while HADS overall mean was 8.4 (SD 6.3).

We observed several statistically significant correlations (with false discovery rate $< =$

0.05) at both baseline and week 12. Measures of dyspnea and overall disease impact

reported by patients showed consistent correlations with clinical measures: the L-IPF

total score was negatively correlated with absolute FVC at baseline ($r = -0.33$,

adjusted $p = 0.03$) and at week 12 ($r = -0.42$, adjusted $p < 0.01$). Similarly, the L-IPF

total score was negatively correlated with 6MWT distance at baseline ($r = -0.43$,

adjusted $p < 0.01$) and week 12 ($r = -0.37$, adjusted $p = 0.02$). Breathlessness-specific

patient-reported outcomes also correlated significantly with FVC, DLCO, 6MWT, and

GAP at one or both time points. For example, the R-scale-PF shortness of breath score

showed negative correlations with absolute DLCO at baseline ($r = -0.35$, adjusted

$p = 0.04$) and more strongly at week 12 ($r = -0.49$, adjusted $p < 0.01$). The K-BILD

Breathlessness and Activities score negatively correlated with GAP score at baseline

($r = -0.42$, adjusted $p = 0.02$) and week 12 ($r = -0.40$, adjusted $p = 0.02$). The K-BILD

total score, where higher scores indicate better health status, positively correlated with

percent-predicted FVC at baseline ($r = 0.38$, adjusted $p = 0.03$) and week 12 ($r = 0.43$,

adjusted $p < 0.01$). Finally, instruments assessing psychological aspects (HADS), and

sleep (PROMIS and ESS) generally showed weaker or non-significant correlations with

the clinical outcomes measured after false discovery rate adjustment.

Our analysis underscores that certain patient reported outcomes, particularly those

focused on respiratory symptoms like dyspnea, correlate with objective clinical

outcomes of lung function and exercise capacity and further capture distinct aspects of

the patient experience. The moderate strength of most observed correlations, even after

rigorous adjustment for multiple comparisons, suggests that patient-reported outcomes

provide unique, complementary information to clinical outcomes, rather than merely

reflecting the same constructs. This aligns with previous research suggesting that

patient-reported outcomes and clinical outcomes can offer different perspectives on a

patient's condition [1]. The application of the Benjamini-Hochberg procedure allowed us to

identify these relationships with controlled false discovery rate, which is particularly

suitable for hypothesis-generating research in pilot studies. The weaker correlations

observed for psychological and sleep-related patient-reported outcomes with

physiological measures highlight the multifaceted impact of idiopathic pulmonary

fibrosis, where these domains may be influenced by factors beyond those captured by

standard lung function tests. We acknowledge limitations for our study findings: small

sample size, single center study, and a short duration of follow up at only 12 weeks;

these issues may limit power to detect weaker correlations.

In conclusion, our analysis demonstrates that, in patients with idiopathic pulmonary

fibrosis, patient-reported outcomes relating to breathlessness and overall disease

impact show significant correlations with established clinical measures at baseline and

follow up at 12 weeks outcomes. The distinct patterns and strengths of these

correlations emphasize that patient-reported outcomes and clinical outcomes are not

interchangeable and offer complementary insights. This work supports the continued

integration of patient-reported outcomes alongside clinical outcomes in clinical trials and

practice to gain a complete understanding of idiopathic pulmonary fibrosis. Given the

observed correlation of patient-reported outcomes with conventional clinical measures

in idiopathic pulmonary clinical trials and practice – a strong rationale exists for utilizing

patient-reported outcomes as surrogate or primary endpoints in future studies to better

capture   patient-centric   benefits.

REFERENCES (10 references at most)

1. Raghu G, Ghazipura M, Fleming TR, et al. Meaningful Endpoints for Idiopathic
Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on "Feels, Functions, Survives".
Report of a Collaborative Discussion in a Symposium with Direct Engagement from
Representatives of Patients, Investigators, the National Institutes of Health, a Patient
Advocacy Organization, and a Regulatory Agency. *Am J Respir Crit Care Med*.
2024;209(6):647-669. doi:10.1164/rccm.202312-2213SO

2. Holland AE, Dowman L, Smallwood N. Patient-reported Outcomes for Clinical Trials
in Idiopathic Pulmonary Fibrosis: New Opportunities to Understand How Patients
Feel and Function. *Am J Respir Crit Care Med*. 2020;202(12):1620-1622.
doi:10.1164/rccm.202007-2775ED

3. Kadura S, Purkayastha S, Benditt J, et al. Yoga Effect on Quality-of-Life Study Among
Patients with Idiopathic Pulmonary Fibrosis (YES-IPF). Published online May 21,
2025:2025.05.20.25327762. doi:10.1101/2025.05.20.25327762

4. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary
Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit*
Care Med. 2018;198(5):e44-e68. doi:10.1164/rccm.201807-1255ST

5. Swigris JJ, Andrae DA, Churney T, et al. Development and Initial Validation Analyses
of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. *Am J Respir Crit Care*
Med. 2020;202(12):1689-1697. doi:10.1164/rccm.202002-0415OC

6. Scallan C, Strand L, Hayes J, et al. R-scale for pulmonary fibrosis: a simple, visual
tool for the assessment of health-related quality of life. *Eur Respir J*.
2022;59(1):2100917. doi:10.1183/13993003.00917-2021

179 7. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's

180  Brief Interstitial Lung Disease (K-BILD) health status questionnaire. *Thorax.*

181  2012;67(9):804-810. doi:10.1136/thoraxjnl-2012-201581

182 8. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS[TM]

183  sleep disturbance and Sleep-Related Impairment item banks. *Behav Sleep Med.*

184  2011;10(1):6-24. doi:10.1080/15402002.2012.636266

185 9. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness

186  scale. *Sleep.* 1991;14(6):540-545. doi:10.1093/sleep/14.6.540

187 10. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and

188  Powerful Approach to Multiple Testing. *Source J R Stat Soc Ser B Methodol.*

189  1995;57(1):289-300.

Table 1: Mean (SD) [Count of Missing Measurements] of patient-reported and clinical outcomes at baseline and week 12 in the YES-IPF trial. Lower scores indicate better symptoms/quality of life for all outcomes except EuroQol-5D-5L scale, King's Brief Interstitial Lung Disease scale, and the 6-minute walking test, where higher scores indicate better status.

Name of outcome		Mean (SD) [# of missing]	
		Baseline	Week 12
Patient-reported outcome	**Living with Idiopathic Pulmonary Fibrosis (L-IPF)**		
	Cough	26.33 (24.20) [0]	21.61 (21.76) [1]
	Dyspnea	23.00 (21.94) [0]	22.08 (21.14) [1]
	Overall	28.67 (19.15) [0]	25.30 (18.26) [1]
	Raghu Scale for Pulmonary Fibrosis (R-scale-PF)		
	Cough	3.03 (2.42) [0]	2.60 (2.48) [2]
	Shortness of Breath	3.70 (2.57) [0]	3.83 (2.75) [2]
	Fatigue	4.05 (2.56) [0]	4.07 (2.97) [2]
	Mood	2.13 (2.33) [0]	1.69 (2.33) [2]
	Wellbeing	2.92 (1.95) [0]	3.34 (2.65) [2]
	Overall	15.83 (9.31) [0]	15.53 (10.33) [2]
	King's Brief Interstitial Lung Disease (K-BILD)		
	Psychological	38.30 (10.37) [0]	39.32 (9.62) [1]
	Breathlessness and Activities	24.80 (8.62) [0]	24.93 (7.86) [1]
	Chest Symptoms	11.48 (2.25) [0]	11.97 (2.14) [1]
	Overall	74.65 (18.15) [0]	76.22 (17.39) [1]
	EuroQol-5D-5L (EQ-5D-5L)		
	Visual Analogue Scale	0.81 (0.11) [0]	0.81 (0.14) [1]
	Index	71.05 (20.22) [0]	69.58 (19.26) [1]
	Hospital Anxiety and Depression Scale (HADS)		
	Anxiety	4.02 (3.47) [0]	3.41 (3.24) [2]
	Depression	4.37 (3.37) [0]	4.02 (3.49) [2]
	Overall	8.38 (6.30) [0]	7.41 (6.07) [2]
	Patient-Reported Outcomes Measurement Information System (PROMIS)		
	Sleep Disturbance	46.95 (9.57) [0]	46.04 (9.10) [2]

	Sleep-Related Impairment	45.97 (9.23) [0]	45.85 (9.37) [2]
	Epworth Sleepiness Scale (ESS)		
	Overall	5.83 (3.65) [0]	5.47 (4.01) [2]
Clinical outcome	Forced Vital Capacity (FVC)		
	Absolute (L)	2.81 (0.82) [0]	2.68 (0.95) [1]
	Percent Predicted (%)	74.80 (21.44) [0]	73.80 (23.47) [1]
	Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO)		
	Absolute (ml/min/kPa)	12.82 (3.93) [1]	11.78 (4.26) [4]
	Percent Predicted (%)	54.22 (18.27) [1]	51.09 (19.99) [4]
	6-minute walking test (6MWT)		
	Overall (feet)	1289.93 (401.68) [2]	1180.55 (459.16) [4]
	Gender-Age-Physiology (GAP) score		
	Overall	3.77 (1.48) [1]	3.77 (1.58) [4]

Table 2: Correlation coefficients (p-values) between patient-reported outcomes and clinical at baseline and week 12 in patients with idiopathic pulmonary fibrosis. P-values are adjusted using the Benjamini-Hochberg method to control for false discovery rate across 21 patient-reported outcomes for each of the 6 clinical outcomes. * Indicates statistical significance at adjusted $p < 0.05$.

	Forced Vital Capacity (FVC)				Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO)				6-minute walking test (6MWT) (feet)		Gender-Age-Physiology (GAP) score	
	Absolute (L)		*Pct. Predicted (%)*		*Absolute (L)*		*Pct. Predicted (%)*					
	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12	Baseline	Week 12
Living with Idiopathic Pulmonary Fibrosis (L-IPF)												
Cough	-0.25 (0.10)	-0.26 (0.07)	-0.30 (0.11)	-0.30 (0.04) *	-0.21 (0.18)	-0.19 (0.23)	-0.21 (0.18)	-0.15 (0.45)	-0.21 (0.17)	-0.13 (0.44)	0.22 (0.25)	0.13 (0.66)
Dyspnea	-0.36 (0.03) *	-0.53 (< 0.01) *	-0.28 (0.11)	-0.57 (< 0.01) *	-0.36 (0.04) *	-0.51 (< 0.01) *	-0.26 (0.18)	-0.35 (0.10)	-0.52 (< 0.01) *	-0.56 (< 0.01) *	0.31 (0.13)	0.47 (< 0.01)*
Overall	-0.33 (0.03) *	-0.42 (< 0.01) *	-0.25 (0.13)	-0.46 (< 0.01) *	-0.31 (0.07)	-0.33 (0.04) *	-0.23 (0.18)	-0.18 (0.35)	-0.43 (< 0.01) *	-0.37 (0.02) *	0.22 (0.25)	0.29 (0.12)
Raghu Scale for Pulmonary Fibrosis (R-scale-PF)												
Cough	-0.09 (0.62)	-0.15 (0.30)	-0.25 (0.13)	-0.15 (0.35)	-0.18 (0.25)	-0.05 (0.78)	-0.25 (0.18)	-0.04 (0.80)	-0.06 (0.74)	0.09 (0.55)	0.23 (0.25)	-0.03 (0.89)
Shortness of Breath	-0.33 (0.03) *	-0.49 (< 0.01) *	-0.32 (0.08)	-0.46 (< 0.01) *	-0.35 (0.04) *	-0.49 (< 0.01) *	-0.28 (0.18)	-0.34 (0.10)	-0.47 (< 0.01) *	-0.43 (< 0.01) *	0.30 (0.13)	0.36 (0.04)*
Fatigue	-0.14 (0.43)	-0.31 (0.04) *	-0.09 (0.62)	-0.21 (0.19)	-0.24 (0.13)	-0.34 (0.03) *	-0.22 (0.18)	-0.13 (0.47)	-0.36 (0.02) *	-0.31 (0.06)	0.12 (0.48)	0.10 (0.69)
Mood	-0.12 (0.50)	-0.19 (0.20)	0.05 (0.74)	-0.04 (0.78)	-0.07 (0.67)	-0.15 (0.35)	0.06 (0.68)	-0.04 (0.79)	-0.13 (0.42)	-0.12 (0.47)	-0.18 (0.34)	-0.08 (0.69)
Wellbeing	-0.33 (0.03) *	-0.35 (0.02) *	-0.21 (0.20)	-0.35 (0.02) *	-0.25 (0.13)	-0.31 (0.05)	-0.20 (0.20)	-0.25 (0.26)	-0.26 (0.10)	-0.30 (0.06)	0.18 (0.34)	0.15 (0.61)
Overall	-0.25 (0.10)	-0.38 (< 0.01) *	-0.21 (0.20)	-0.32 (0.03) *	-0.28 (0.09)	-0.35 (0.03) *	-0.23 (0.18)	-0.21 (0.31)	-0.33 (0.03) *	-0.29 (0.07)	0.17 (0.34)	0.14 (0.63)
King's Brief Interstitial Lung Disease (K-BILD)												

Psychological	0.26 (0.10)	0.29 (0.05)	0.29 (0.11)	0.28 (0.06)	0.14 (0.41)	0.24 (0.13)	0.07 (0.68)	0.18 (0.35)	0.25 (0.10)	0.18 (0.26)	-0.10 (0.57)	-0.09 (0.69)
Breathlessness and Activities	0.35 (0.03) *	0.44 (< 0.01) *	0.39 (0.03) *	0.51 (< 0.01) *	0.42 (0.02) *	0.43 (< 0.01) *	0.31 (0.18)	0.33 (0.10)	0.54 (< 0.01) *	0.44 (< 0.01) *	-0.42 (0.02)*	-0.40 (0.02)*
Chest Symptoms	0.14 (0.43)	0.26 (0.07)	0.20 (0.22)	0.37 (0.01) *	0.23 (0.15)	0.17 (0.31)	0.24 (0.18)	0.13 (0.47)	0.13 (0.42)	0.19 (0.26)	-0.13 (0.46)	-0.09 (0.69)
Overall	0.34 (0.03) *	0.39 (< 0.01) *	0.38 (0.03) *	0.43 (< 0.01) *	0.31 (0.07)	0.35 (0.03) *	0.22 (0.18)	0.26 (0.26)	0.42 (< 0.01) *	0.32 (0.05)	-0.27 (0.18)	-0.24 (0.24)
EuroQol-5D-5L (EQ-5D-5L)												
Visual Analogue Scale	0.28 (0.09)	0.35 (0.02) *	0.26 (0.13)	0.36 (0.02) *	0.25 (0.13)	0.33 (0.03) *	0.22 (0.18)	0.21 (0.31)	0.33 (0.03) *	0.44 (< 0.01) *	-0.26 (0.19)	-0.29 (0.12)
Index	0.34 (0.03) *	0.38 (< 0.01) *	0.19 (0.25)	0.39 (< 0.01) *	0.30 (0.07)	0.34 (0.03) *	0.16 (0.31)	0.24 (0.26)	0.49 (< 0.01) *	0.46 (< 0.01) *	-0.11 (0.51)	-0.16 (0.56)
Hospital Anxiety and Depression Scale (HADS)												
Anxiety	-0.05 (0.75)	-0.35 (0.02) *	0.09 (0.62)	-0.20 (0.22)	0.09 (0.67)	-0.15 (0.36)	0.22 (0.18)	-0.05 (0.79)	-0.09 (0.63)	-0.19 (0.26)	-0.20 (0.30)	-0.02 (0.90)
Depression	-0.17 (0.34)	-0.15 (0.30)	0.01 (0.95)	-0.10 (0.52)	-0.22 (0.16)	-0.27 (0.09)	-0.10 (0.54)	-0.18 (0.35)	-0.32 (0.03) *	-0.30 (0.06)	0.07 (0.69)	0.08 (0.69)
Overall	-0.12 (0.50)	-0.28 (0.06)	0.05 (0.74)	-0.16 (0.32)	-0.07 (0.67)	-0.24 (0.14)	0.07 (0.68)	-0.13 (0.47)	-0.22 (0.16)	-0.28 (0.08)	-0.07 (0.67)	0.04 (0.89)
Patient-Reported Outcomes Measurement Information System (PROMIS)												
Sleep Disturbance	-0.07 (0.70)	-0.11 (0.43)	-0.09 (0.62)	-0.00 (0.99)	-0.01 (0.93)	-0.01 (0.94)	-0.06 (0.68)	0.04 (0.79)	0.03 (0.90)	0.08 (0.60)	-0.05 (0.75)	-0.18 (0.50)
Sleep-Related Impairment	-0.02 (0.91)	-0.22 (0.13)	0.10 (0.62)	-0.11 (0.50)	0.08 (0.67)	-0.04 (0.81)	0.16 (0.31)	0.09 (0.64)	-0.01 (0.95)	-0.10 (0.55)	-0.13 (0.46)	-0.11 (0.69)
Epworth Sleepiness Scale (ESS)												
Overall	0.02 (0.91)	-0.09 (0.51)	-0.05 (0.74)	-0.11 (0.50)	0.03 (0.84)	0.11 (0.50)	0.11 (0.54)	0.24 (0.26)	-0.01 (0.95)	0.06 (0.66)	0.02 (0.89)	-0.03 (0.89)